NervGen Sets Advisory Board to Support Upcoming NVG-291 Trial

NervGen Sets Advisory Board to Support Upcoming NVG-291 Trial

299802

NervGen Sets Advisory Board to Support Upcoming NVG-291 Trial

NervGen Pharma announced the formation of its multiple sclerosis (MS) clinical advisory board, a group of experts who will work with the company as it prepares to start a Phase 2 clinical trial next year testing its lead compound, NVG-291, in people with MS. “We are honored to have assembled such an esteemed and dedicated group of experts willing to share their combined decades of experience to advise us on our upcoming Phase 2 study…

You must be logged in to read/download the full post.